For example, the combined low-dose treatment of rhabdomyosarcoma with the proteasome inhibitor Bortezomib (5–7.5 nM) plus the HSP90 inhibitor 17-DMAG (≤50 nM) exhibited greater efficacy than either single agent with improved side effects [265]. The gene discussed is HSP90AB1; the disease is rhabdomyosarcoma.